SuperworthElevance Health Inc. ELV
Medical - Healthcare Plans, Healthcare
$404.31
+1.05%
- Market cap
- $87.7B
- PE
- 18.0×
- 10y median 17.6×
- Forward PE
- Price to sales
- 0.4×
- EV/EBIT
- 11.1×
- Revenue, 12 months
- $201.1B
- +6% on a year ago
- Net margin
- 2.5%
- Free cash flow yield
- 7.2%
Elevance Health trades at 18.0× trailing earnings, near its ten-year median. Revenue was $201.1B over the last twelve months, up 6% on a year earlier with a 2% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $42.6B | $42.6B | $43.9B | $45.1B | $45.4B+7% | $48.9B+15% | $49.8B+13% | $50.7B+12% | $49.7B+10% | $50.2B+3% | $50.5B+1% | |
| Cost of revenue | $31.3B | $30.5B | $30.6B | $32.9B | $33.5B+7% | $35.3B+16% | $36.7B+20% | $38.1B+16% | $38.1B+14% | $35.6B+1% | $37B+1% |
| Gross profit | $11.3B | $12B | $13.3B | $12.2B | $11.9B+6% | $13.6B+13% | $13.1B−2% | $12.6B+3% | $11.7B−2% | $14.6B+7% | $13.4B+3% |
| SG&A | $5B | $4.9B | $5.1B | $5.3B | $4.8B−4% | $5.3B+9% | $5B−1% | $5.3B+0% | $5.4B+13% | $6.3B+19% | $5.5B+11% |
| $1.3B | $3.2B | $3B | $1.7B | $946M−25% | $3.1B−2% | $2.6B−13% | $1.8B+3% | $581M−39% | $2.7B−15% | $2.1B−22% | |
| Interest expense | $259M | $265M | $280M | $300M | $340M+31% | $344M+30% | $341M+22% | $351M+17% | $366M+8% | $357M+4% | $56M−84% |
| Pre-tax income | $1B | $2.9B | $3B | $1.4B | $606M−40% | $2.8B−5% | $2.3B−23% | $1.4B+2% | $215M−65% | $2.3B−18% | $1.9B−16% |
| $170M | $690M | $685M | $365M | $193M+14% | $613M−11% | $548M−20% | $219M−40% | −$331M | $544M−11% | $483M−12% | |
| Net income | $856M | $2.2B | $2.3B | $1B | $418M−51% | $2.2B−3% | $1.7B−24% | $1.2B+17% | $547M+31% | $1.8B−19% | $1.5B−16% |
| $3.63 | $9.59 | $9.85 | $4.36 | $1.81−50% | $9.61+0% | $7.72−22% | $5.32+22% | $2.47+37% | $8.00−17% | $6.71−13% | |
| 235.8M | 234.2M | 233.4M | 233.1M | 231.1M−2% | 227.2M−3% | 225.8M−3% | 223.7M−4% | 221.8M−4% | 220.4M−3% | 217.9M−4% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Healthcare Plans within ten times Elevance Health's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ELVElevance Health Inc. | $87.7B | 18.0× | 17.6× | 0.4× | +6% | 2.5% | |
| CICigna Corporation | $73.6B | 11.5× | 16.1× | 0.3× | +8% | 2.3% | |
| CVSCVS Health Corp. | $112.5B | 23.3× | 16.2× | 0.3× | +7% | 1.2% | |
| HUMHumana Inc. | $47.6B | 37.5× | 20.5× | 0.3× | +18% | 0.9% | |
| UNHUnitedHealth Group Incorporated | $337.5B | 24.2× | 22.4× | 0.7× | +6% | 3.1% | |
| Peer median | $93B | 23.7× | 18.4× | 0.3× | +8% | 1.7% |
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .